Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 509-513

  Rojewski, Markus Thomas ^a   Korper, Sixten ^a   Thiel, Eckhard ^b   Schrezenmeier, Hubert ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Arsenic trioxide; CD95; Fas; Lymphoma

Indexed keywords

ANTIBODY; ARSENIC TRIOXIDE; FAS ANTIGEN; GLUTAMIC ACID; GROWTH INHIBITOR; LEUKOCYTE ANTIGEN; ORGANOARSENIC DERIVATIVE; OXIDE;

APOPTOSIS; ARTICLE; CELL MEMBRANE POTENTIAL; CELL STRAIN HL 60; CELL STRAIN K 562; DRUG EFFECT; HUMAN; IMMUNOLOGY; INTRACELLULAR MEMBRANE; LEUKEMIA CELL LINE; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD95; APOPTOSIS; ARSENICALS; GLUTAMIC ACID; GROWTH INHIBITORS; HL-60 CELLS; HUMANS; INTRACELLULAR MEMBRANES; JURKAT CELLS; K562 CELLS; MEMBRANE POTENTIALS; MITOCHONDRIA; OXIDES;

EID: 3242797582     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.509     Document Type: Article

References (39)

1. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324, 1999. (Pubitemid 29536124)
2. Ohnishi K, Yoshida H, Shigeno K, et al: Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16: 617-622, 2002. (Pubitemid 34449742)
3. Soignet SL: Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6: 11-16, 2001.
4. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001. (Pubitemid 32880064)
5. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998. (Pubitemid 28509343)
6. Camacho LH, Soignet SL, Chanel S, et al: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18: 2620-2625, 2000. (Pubitemid 30432530)
7. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M and Srivastava A: Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 70: 292-299, 2002. (Pubitemid 34810506)
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
9. Warrell RP Jr, Soignet SL, Maslak P, et al: Initial Western study of arsenic trioxide in acute promyelocytic leukemia. J Clin Oncol 17:S19, 1998.
10. Spencer A and Firkin F: Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. Aust N Z J Med 29: 385-386, 1999. (Pubitemid 29322916)
11. Hu J, Shen Z, Sun H, et al: Long-term survey of outcome in acute promyelocytic leukemia. Chin Med J 113: 107-110, 2000. (Pubitemid 30176439)
12. 3 : an experience of 120 patients at a single institution. Int J Hematol 70: 248-260, 1999.
13. Munshi NC, Tricot G, Desikan R, et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16:1835-1837, 2002.
14. Munshi NC: Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 6: 17-21, 2001.
15. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002. (Pubitemid 35424755)
16. Berenson JR, Yang H, Vescio R, Swift R, Sadler K and Ellison R: Preliminary findings in a phase 1/2 study of Trisenox(R) (arsenic trioxide) dosed twice weekly in patients with advanced multiple myeloma. Hematol J 4: S255, 2003.
17. Hussein MA, Elson P, Reed J, et al: Arsenic trioxide (Trisenox™), ascorbic acid (AA), and dexamethasone (Dex) pulses-TAD for relapsed refractory progressive multiple myeloma patients. Hematol J 4: S257, 2003.
18. List AF: New approaches to the treatment of myelodysplasia. Oncologist 7: 39-49, 2002.
19. Dutcher JP, Wiernik PH and Garl S: Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO). Blood 96: 260b, 2000. (Pubitemid 33782324)
20. Vuky J, Yu R, Schwartz L and Motzer RJ: Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 20: 327-330, 2002. (Pubitemid 34823761)
21. 3) on non-acute promyelocyte leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 116: 555-563, 2002.
22. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999. (Pubitemid 29322782)
23. Ora I, Bondesson L, Jonsson C, et al: Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 277: 179-185, 2000.
24. Nakagawa Y, Akao Y, Morikawa H, et al: Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-2269, 2002. (Pubitemid 34251296)
25. Liu L, Qin S, Chen H, Wang J, Ma J and Liu W: An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes. Chung Hua Kan Tsang Ping Tsa Chih 8: 367-369, 2000.
26. Pu YS, Hour TC, Chen J, Huang CY, Guan JY and Lu SH: Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 13: 293-300, 2002. (Pubitemid 34492711)
27. Deng Y, Lin C, Zheng J, et al: Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide. Chin Med J 113: 84-88, 2000. (Pubitemid 30176239)
28. Urn SJ, Lee SY, Kim EJ, Myoung J, Namkoong SE and Park JS: Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett 181: 11-22, 2002. (Pubitemid 34310657)
29. Vogt BL and Rossman TG: Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - a possible mechanism for arsenite's comutagenicity. Mutat Res 478: 159-168, 2001. (Pubitemid 32530861)
30. Woo SH, Park IC, Park MJ, et al: Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 21: 57-63, 2002.
31. Jiang XH, Wong BC, Yuen ST, et al: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 91: 173-179, 2001. (Pubitemid 32041736)
32. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999. (Pubitemid 29359187)
33. Debatin KM, Beitinger C, Bohler T, et al: Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans 25: 405-410, 1997.
34. Liu J, Kadiiska MB, Liu Y, Lu T, Qu W and Waalkes MP: Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol Sci 61: 314-320, 2001. (Pubitemid 32499399)
35. Liu Q, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent Gl or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087, 2003. (Pubitemid 36857889)
36. Mak NK, Wong RN, Leung KN and Fung M: Involvement of tumor necrosis factor (TNF-alpha) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. Toxicol Lett 135:79-87, 2002. (Pubitemid 35276538)
37. Tsai S, Hsieh M, Chen L, Liang Y, Lin J and Lin S: Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicol Lett 123: 11-19, 2001. (Pubitemid 32763084)
38. Zhu J, Okumura H, Ohtake S, Nakamura S and Nakao S: Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 10: 705-709, 2003.
39. Poulaki V, Mitsiades CS and Mitsiades N: The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Update 4: 233-242, 2001. (Pubitemid 34456377)